Table 3.
Intervention trials of PUFAs in ADHD.
| Study | Sample (N and Mean Age, in Years) | Intervention | Results |
|---|---|---|---|
| Döpfner et al. (2021) [75] | N = 40 A (intervention group) = 5.5 ± 0.61 A (placebo group) = 4.97 ± 0.93 |
Two capsules of an Omega-3/Omega-6 fatty acid supplement twice a day, corresponding to a daily dose of 372 mg EPA, 116 mg DHA, and 40 mg GLA 16 weeks |
+ Parent- and teacher-rated ADHD symptoms, parent-rated internalizing symptoms, and parent- and teacher-rated externalizing symptoms in intention-to-treat analyses + Teacher-rated inattention symptoms and parent-rated internalizing problems in analyses involving all available data x Intellectual abilities in either of the analyses |
| Carucci et al. (2022) [76] | N = 160 Age = 9.7 ± 1.9 |
Two capsules containing 279 mg EPA, 87 mg DHA, 30 mg GLA (gamma linolenic acid) or placebo/day 6 months double-blind (phase 1) 6 months open-label (phase 2) |
x ADHD RS inattention score after phase 1 + ADHD RS total score after 12 months |
+ = improvements; x = no improvements.